On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC
Program Overview
Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy, privileged insights into optimal therapeutic selection based on the latest clinical trial data, and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.
This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).
Educational Objectives
Upon completion of this activity, participants should be better able to:
Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC
Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial
Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting
Activity Faculty
Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology)and Professor, Pharmacology
Chief, Medical Oncology
Yale Cancer Center and Smilow Cancer Hospital
Associate Cancer Center Director, Translational Research
Yale Cancer Center
New Haven, CT
Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)